Nyth A L, Gottfries C G
University of Göteborg, Department of Psychiatry and Neurochemistry, St Jörgen's Hospital, Hisings-Backa, Sweden.
Br J Psychiatry. 1990 Dec;157:894-901. doi: 10.1192/bjp.157.6.894.
In this multicenter study, the clinical efficacy of citalopram was investigated in 98 patients with moderate AD/SDAT or VD using a combined double-blind and open technique with placebo and citalopram. Analyses were made for each diagnosis after four weeks of double-blind treatment. Patients with AD/SDAT treated with citalopram showed a significant improvement in emotional bluntness, confusion, irritability, anxiety, fear/panic, depressed mood and restlessness. Those improvements were not found after treatment with placebo. There were no significant improvements in patients with VD. No improvements were recorded in motor or cognitive impairment. Citalopram provoked few and comparatively mild side-effects. None of the changes observed during the double-blind withdrawal period were identified as withdrawal symptoms or rebound phenomena.
在这项多中心研究中,采用双盲与开放相结合的技术,使用安慰剂和西酞普兰,对98例中度阿尔茨海默病/老年性痴呆或血管性痴呆患者研究了西酞普兰的临床疗效。双盲治疗四周后,对每种诊断进行分析。接受西酞普兰治疗的阿尔茨海默病/老年性痴呆患者在情感迟钝、意识模糊、易怒、焦虑、恐惧/惊恐、情绪低落和坐立不安方面有显著改善。安慰剂治疗后未发现这些改善。血管性痴呆患者无显著改善。运动或认知障碍方面无改善记录。西酞普兰引起的副作用较少且相对较轻。在双盲撤药期观察到的变化均未被确定为撤药症状或反跳现象。